Hansa Biopharma enrolls first patient in U.S. randomized, controlled pivotal trial of imlifidase in highly sensitized kidney transplant patients
· Hansa expects to complete enrollment in the second half of 2022 with a 12-month follow up completed in the second half of 2023 · The U.S. randomized, controlled trial is expected to support a potential Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) under accelerated approval pathway in the first half of 2024Lund, Sweden December 29, 2021. Hansa Biopharma AB “Hansa”, (Nasdaq Stockholm: HNSA), the pioneer in IgG-cleaving enzyme technology for rare immunological conditions, today announces that the first patient in its U.S. open-label,
